National Comprehensive Cancer Network

Educational Events & Programs

NCCN 15^th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™

2010 NCCN Pharmacy Program:
Best Practices in Oncology Pharmacy Management™
Wednesday, March 10, 2010

Join us at the NCCN 15^th Annual Conference and 2010 NCCN Pharmacy Program: Best Practices in Oncology Pharmacy Management™. This half-day, pre-conference program is designed specifically for pharmacists.

Register Now - for the 2010 NCCN Pharmacy Program and also receive FREE registration for the NCCN 15th Annual Conference.*

Program Overview
The oncology pharmacist plays a pivotal role in developing and administering formulary policies that provide patient access to safe and appropriate use of drugs and biologics. This program consists of presentations which will focus on regulatory initiatives including risk evaluation and mitigation strategies (REMS) and biosimilars; payor programs including comparative effectiveness, specialty pharmacy, orals and disease management; and the implications of biomarkers in pharmacy practice.

Educational Objectives
Following this program, participants should be able to:

• Describe the regulations and policies surrounding REMS
• Identify the potential impact of REMS on daily pharmacy practice
• Describe the basic requirements of REMS in cancer care
• Describe the issues surrounding specialty pharmacies and oncology practice with regard to infusion center “brown bagging”, disease state management programs, and closed distribution of oral anti-cancer agents
• List issues surrounding specialty pharmacy and oncology practice
• Identify ways in which payors could incorporate comparative effectiveness results into policy
• Define “biomarker” and list examples of cancer biomarkers
• Explain how biomarkers are currently used in the daily practice of cancer medicine
• Describe how the emerging science with biomarkers will affect the future of cancer medicine

Preliminary Agenda - Wednesday, March 10, 2010
12:15 – 5:00 PM

• Biomarkers: Implications for Practice
• REMS: Implementation and Implications for Academic and Community Oncology Pharmacies
• Payor Programs: Compendia, Specialty Pharmacy, Orals and Disease Management, Comparative Effectiveness, and Reimbursement

Agenda and faculty are subject to change.

Accreditation
NCCN will work with the Postgraduate Institute for Medicine (PIM) to obtain certification of the activity for pharmacists.

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, and Cephalon Oncology.

Pharmacist Continuing Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Specific learning objectives and the Universal Activity Number will be available prior to the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Fee Information

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 3 weeks.

Intended Audience
This educational activity is designed to meet the educational needs of pharmacists who manage patients with cancer.

Accommodations

Airline Travel

Educational Opportunity Exclusively for Pharmacists. Register Now – Space is limited.

*Employment through industry precludes free conference registration that is offered to attendees of the NCCN Pharmacy Program; attendance at the NCCN Pharmacy Program is only if space permits.